Affinergy

Home

Technology

Leadership

About Us


Technology




Affinergy's Platform Technology




Affinergy has developed a phage display platform capable of identifying peptides that bind to a wide variety of targets (e.g.; drugs, proteins, cells). Affinergy's technology ushers in a new era of flexible, personalized care.

Our assay platform does not rely on antibodies. As a result, the assay development process can be quickly replicated for a diverse range of assay targets. We have focused our product development efforts on two key areas:

  • Therapeutic drug monitoring assays using Affinergy's proprietary capture and detection reagents
  • Peptide-mediated capture of clinically relevant, but low abundance, cell types from patient specimens onto glass slides



Applications




PhageLock

Therapeutic Drug Monitoring


Affinergy has developed pairs of capture and detection reagents which are particularly well-suited to developing assays for diagnostic targets that are problematic for traditional antibody-based approaches (e.g. low immunogenicity, highly conserved target, etc.).

The capture reagent binds an analyte from a patient specimen (whole blood, plasma, serum) and the analyte is then directly detected through binding of a locking and detection reagent, which only recognizes the analyte when in complex with the capture reagent.





Peptide-mediated Cell Capture on Slides


Patient specimens come in a variety of biofluids (blood, sputum, saliva, fine-needle aspirate, urine). Depending on the specimen composition, Affinergy's cell-specific peptides can be added to the patient specimen directly or covalently attached to glass slides.

Slide capture Affinergy has already developed peptides capable of recognizing mesenchymal stem cells, urothelial cells, and podocytes with high affinity and specificity. Peptide-mediated capture onto a slide's capture zone allows the rapid enrichment and concentration of a cell type of interest, while separating away cell types that are obscuring or irrelevant.




Affinergy's products are not currently approved by the U.S. Food and Drug Administration.





Example Peptides




Affinergy has discovered proprietary peptides that bind with high affinity and specificity to multiple targets, including the following:

spacer

Growth Factors:

  • BMP-2 and BMP-7

  • PDGF-BB

  • TGFβ3

spacer

Cells:

  • Mesenchymal Stem Cells

  • Fibroblasts

  • Epithelial Cells

  • Cardiomyocytes

  • Regulatory T cells

  • Monocytes

  • Hepatocytes

spacer

Antibiotics:

  • Vancomycin





Sample Publications








Compliance




Click here to view Affinergy's Financial Conflict of Interest Policy.





Support




Affinergy is grateful to the following institutes for funding its research endeavors:

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institute of Dental and Craniofacial Research

National Institute of General Medical Sciences

National Heart, Lung, and Blood Institute

National Institute of Allergy and Infectious Diseases

National Institute of Diabetes and Digestive and Kidney Diseases

National Institute of Neurological Disorders and Stroke